Science&Humans closes oversubscribed $10M Series A as hormone health moves into the mainstream
Canadian healthtech
Canadian healthcare technology company Science&Humans has closed an oversubscribed $10M Series A round, combining equity and debt financing, as investor and employer interest in hormone health accelerates.
The round was led by Pender Ventures, with participation from WELL Health Technologies Corp., entrepreneur and investor Michele Romanow, CIBC Innovation Banking, U.S.-based healthcare investors, and a group of internationally recognised physicians and longevity experts.
The financing lands at a moment when hormone health is gaining recognition as a foundational driver of physical health, mental wellbeing, workplace participation, and long-term healthcare costs for both women and men.
Founded by Hira Siddiqui and Aftab Pashaw, Science&Humans was built on the premise that hormones function as the body’s core regulatory system, influencing mood, cognition, sleep, metabolism, fertility, cardiovascular health, and aging.
Science&Humans says the new capital will be used to expand its technology and clinical platform, scale nationwide access to hormone and longevity care, deepen partnerships with employers and insurers, and advance prevention- and outcomes-based care models.
Hormone health steps out of the margins
Hormone-related conditions span the entire lifespan, from PCOS, PMS, PMDD and endometriosis, through fertility challenges, perimenopause and menopause, to obesity, metabolic dysfunction and andropause. Yet many patients spend years, sometimes decades, cycling through symptoms without coordinated, evidence-based care.
The economic consequences are becoming harder to ignore. McKinsey has estimated that closing gaps in women’s health could unlock up to $37 billion in annual economic value in Canada alone, driven by improved workforce participation, productivity, and long-term health outcomes.
Midlife hormonal transitions are a particularly acute pressure point. Perimenopause and menopause have been linked to rising rates of mental health challenges, absenteeism, and workforce attrition. Research has also associated midlife hormonal shifts—such as mood changes and reduced libido—with higher divorce rates, underlining how deeply hormone health can shape social and economic outcomes over a decade-long window.
“Hormone health is moving into the mainstream in much the same way mental health did a decade ago,” said Romanow.
“What Science&Humans has built is a scalable, clinically grounded approach to an area of healthcare that has long been underserved, despite its profound impact on people’s lives and economic participation.”
A platform built around precision
Rather than standardised prescribing, the company has developed proprietary, evidence-based clinical protocols designed to deliver precision dosing and personalised treatment. Its model emphasises diagnostics, continuous monitoring, clinician oversight, and life-stage context—aiming to reduce overprescription while improving outcomes.
Science&Humans says it has now served more than 50,000 Canadians nationwide, with over 80% of patients reporting meaningful symptom improvement within 90 days. Care is delivered through a vertically integrated platform spanning direct-to-consumer services and employer and insurer partnerships.
“Science&Humans has built a differentiated, evidence-based platform for hormone care—an area that has been historically underdiagnosed and underserved,” said Meryeme Lahmami, principal at Pender Ventures.
“Their vertically integrated model enables consistent, high-quality care at scale through employers and insurers.”
Regulatory and employer tailwinds
The company is also benefiting from shifting regulatory and employer dynamics. In the U.S., the U.S. Food and Drug Administration has recently removed boxed warnings on certain hormone replacement therapies, reflecting updated clinical evidence and helping to rebuild confidence in appropriately prescribed hormone care.
At the same time, employers and insurance carriers are increasingly incorporating hormone health into workplace wellness and benefits programmes. The rationale is that unmanaged hormone symptoms can drive absenteeism, mental health claims, reduced productivity, and elevated chronic disease risk.
Science&Humans positions itself as an enterprise-grade partner across these channels, supporting individuals, employers, insurers, and healthcare organisations—an approach that remains relatively rare in the Canadian healthcare landscape.
“Hormone health was not treated as a category in Canada when we started,” said Pashaw, co-founder and CEO.
“This funding reflects a broader shift in how healthcare systems, employers, and patients are thinking about daily wellness, mental health, and long-term outcomes.”